1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
McKesson Corporation

McKesson Corporation

MCK
McKesson CorporationUS flagNew York Stock Exchange
881.51
USD
+0.65
- -
103.21BMarket Cap
McKesson Corporation
MCK
(New York Stock Exchange)

Recent

price

881.51

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
434.43
497.24
519.98
599.97
771.75
829.93
898.34
1,001.72
1,093.46
1,276.52
1,483.36
1,733.2
1,961.1
2,319.45
2,818.3
3,264
3,368.71
Revenue per Share
4.66
5.7
5.69
5.52
6.36
9.82
22.94
0.32
0.17
4.97
-28.26
7.31
25.23
22.54
25.86
38.53
37.64
Basic EPS, GAAP
7.56
10.37
8.86
11.86
11.06
13.02
18.92
18.1
17.75
21.37
24.29
26.57
33.8
29.15
43.55
46.27
52.59
Free Cash Flow per Basic Share
0.66
0.79
0.83
0.93
0.98
1.06
1.14
1.26
1.49
1.62
1.72
1.82
2.07
2.36
2.71
3.08
3.22
Dividend per Share
28.65
29.07
31.15
36.89
34.49
39.66
52.58
48.53
42.6
31.43
-0.13
-15.67
-13.65
-15.11
-16.59
-18.1
-36.55
Book Value per Share
4.95
0.21
-7.07
-27.17
-22.66
-17.26
-14.96
-25.85
-26.07
-45.83
-78.43
-95.05
-103.54
-108.99
-108.48
-146.39
-168.37
Tangible Book Value per Share
258
246
235
229
232
230
221
208
196
181
161
152
141
133
127
124
122
Basic Weighted Avg Shares
112,084
122,321
122,196
137,392
179,045
190,884
198,533
208,357
214,319
231,051
238,228
263,966
276,711
308,951
359,051
403,430
410,983
Sales/Revenue/Turnover
1.81
1.86
1.91
1.82
1.74
1.91
1.75
1.4
1.55
1.23
1.38
0.98
1.66
1.35
1.34
1.6
1.65
Operating Margin (%)
496
493
581
735
1,017
885
910
951
949
922
887
760
608
635
636
729
767
Depreciation Expense
1,202
1,403
1,338
1,263
1,476
2,258
5,070
67
34
900
-4,539
1,114
3,560
3,002
3,295
4,762
4,592
Net Income, GAAP
30.89
27.15
30.1
34.87
30.67
27.94
23.42
- -
58.36
1.57
- -
32.99
19.55
16.6
20.14
17.77
17.93
Effective Tax Rate (%)
1.07
1.15
1.09
0.92
0.82
1.18
2.55
0.03
0.02
0.39
-1.91
0.42
1.29
0.97
0.92
1.18
1.12
Profit Margin (%)
3,631
1,917
1,813
3,221
3,173
3,366
1,336
451
839
-402
1,279
-2,235
-3,665
-4,387
-6,206
-9,807
-7,519
Working Capital
3,587
3,072
4,521
8,929
8,180
6,497
7,305
6,751
7,265
7,995
8,273
6,446
6,028
7,045
5,941
7,060
10,112
LT Debt
7,220
6,831
7,070
10,318
9,471
10,414
12,600
11,516
9,680
6,711
1,446
-1,792
-1,490
-1,599
-1,694
-834
-1,301
Total Equity
12.19
13.77
12.89
9.05
9.91
13.24
13.45
- -
7.53
16.75
- -
20.93
63.81
60
66.96
78.76
57.26
Return on Invested Capital (%)
12.88
14.39
13.24
8.91
8.29
13
26.33
- -
-0.42
5.54
- -
12.77
62.27
52.68
57.82
68.69
42.22
Return on Capital (%)
16.3
19.97
19.25
16.2
17.87
26.68
50.65
0.64
0.38
13.65
-42.76
12.93
33.38
22.01
20.03
23.68
69.51
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
1,418
1,554
1,589
LT Borrowings
5,425
5,259
8,432
LT Finance Leases
1,781
1,801
1,680
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
123
120
116
Market Capitalization
100,896
103,843
87,650

Working Capital

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
59,697
57,210
62,837
Cash, Cash Equivalents & STI
2,959
3,975
5,164
Accounts Receivable, Net
28,213
24,247
30,316
Inventories
27,067
24,207
26,259
Total Current Liabilities
68,131
67,017
70,356
Payables & Accruals
66,713
65,463
68,767
ST Debt
1,418
1,554
1,589
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-39.1%
-55.66%
-50.77%
Free Cash Flow
8.31%
9.79%
3.08%
Net Income, GAAP
205.3%
26.73%
44.52%
Sales/Revenue/Turnover
7.86%
11.17%
12.36%
Total Cash Common Dividend
4.69%
6.72%
10.43%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
79,283
93,651
95,294
90,823
359,051
2026
97,827
103,150
106,158
96,295
403,430
2027
105,380
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
7.05
1.87
6.98
10.06
25.86
2026
6.28
8.95
9.63
13.78
38.53
2027
5.17
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.63
0.62
0.73
0.73
2.71
2026
0.72
0.72
0.82
0.83
3.08
2027
0.86
- -
- -
- -
- -
Similar Companies
Sopharma AD (SPH.WA)
Sipai Health Technology Co., Ltd. (0314.HK)
Cardinal Health, Inc. (0HTG.L)
Oriola Oyj (OKDAV.HE)
PT Millennium Pharmacon International Tbk (SDPC.JK)
Cellyan Biotechnology Co., Ltd (HKPD)
Business
McKesson Corporation (NYSE: MCK) operates as a diversified healthcare services company, primarily engaged in pharmaceutical distribution, medical-surgical supply distribution, oncology and multispecialty solutions, and prescription technology services. The company distributes pharmaceuticals and medical supplies through its North American Pharmaceutical segment, which serves retail and community pharmacies, specialty care settings, and health systems across the United States and Canada via a network of distribution centers; its Oncology and Multispecialty segment provides practice management, technology solutions, specialty drug distribution, clinical trial services, group purchasing, and pharmacy solutions for community-based oncology practices and providers in retina and ophthalmology; its Medical-Surgical Solutions segment merchandises and distributes more than 285,000 national brand products alongside McKesson's own brands of medical-surgical supplies, pharmaceuticals, laboratory equipment, and supplies to physician offices, surgery centers, long-term care providers, home health agencies, health systems, government facilities, and online retailers in the United States; and its Prescription Technology Solutions segment offers medication access, affordability, and adherence programs, including prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support connecting patients, pharmacies, providers, payers, and biopharma companies. [fetch:https://www.mckesson.com/about-us/business-segments/] Founded in 1833 and headquartered in Irving, Texas, McKesson serves healthcare providers, pharmacies, biopharma manufacturers, governments, and consumers primarily in North America, with additional distribution and retail operations in Norway, which it agreed to sell in August 2025. [fetch:https://www.mckesson.com/about-us/history/] In recent strategic developments, McKesson acquired a controlling interest in Community Oncology Revitalization Enterprise Ventures (Core Ventures), associated with Florida Cancer Specialists & Research Institute, for $2.49 billion in August 2024 to bolster oncology care; welcomed Florida Cancer Specialists as a member of The US Oncology Network; acquired a controlling interest in PRISM Vision Group to expand into ophthalmology and retina care; formed a joint venture between US Oncology Research and HCA Healthcare's Sarah Cannon Research Institute to advance oncology research and clinical trials; and announced in September 2025 a corporate restructuring into four segments—North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions—effective fiscal 2026, alongside plans to separate the Medical-Surgical Solutions segment and updated long-term growth targets including 13% to 16% adjusted earnings per share growth. [fetch:https://www.mckesson.com/about-us/history/]

Company News

Company News APIChatGPT

  • defenseworld.net

    Baird Financial Group Inc. Has $29.98 Million Holdings in McKesson Corporation $MCK

  • defenseworld.net

    McKesson Corporation $MCK Shares Sold by Allworth Financial LP

  • zacks.com

    McKesson (MCK) Suffers a Larger Drop Than the General Market: Key Insights

  • businesswire.com

    PRIVACY ALERT: AWKO Law LLP Investigating McKesson for Data Breach Affecting 284 Million Patient Records

  • zacks.com

    McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It

  • seekingalpha.com

    McKesson Corporation (MCK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

  • marketbeat.com

    McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

  • seekingalpha.com

    Underestimating The Moat: Why McKesson's Oncology Pivot And Share Buybacks Signal Structural Upside

  • defenseworld.net

    McKesson Corporation $MCK Shares Acquired by Barlow Wealth Partners LLC

  • zacks.com

    Here's Why McKesson (MCK) is a Strong Momentum Stock

  • zacks.com

    Here's Why McKesson (MCK) is a Strong Growth Stock

  • techcrunch.com

    Hackers claim millions of patient records stolen during data breach at healthcare giant McKesson

  • defenseworld.net

    Beacon Pointe Advisors LLC Purchases New Stake in McKesson Corporation $MCK

  • zacks.com

    McKesson to Acquire Precision Medicine Group to Strengthen Services

  • zacks.com

    Here's Why You Should Retain McKesson Stock in Your Portfolio for Now

  • benzinga.com

    McKesson Buys Precision Medicine to Expand Clinical Research and Commercialization

  • reuters.com

    McKesson to buy Precision Medicine Group in about $2.25 billion deal

  • businesswire.com

    McKesson Signs Agreement to Acquire Precision Medicine Group, LLC

  • zacks.com

    McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate

  • zacks.com

    Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?